Answers are grounded in this paper and cite their sources.
As a cutting-edge non-viral delivery system, lipid nanoparticles (LNPs) are revolutionizing the treatment of drugs and nucleic acids. LNPs are now recognized as adaptable, clinically validated nanocarriers due to their clinical success, as evidenced by approved siRNA therapies and extensively used mRNA vaccines. In order to facilitate effective intracellular cargo release, modern LNPs employ ionizable lipids, which are neutral under physiological conditions but become positively charged in acidic endosomes. Stability, encapsulation efficiency, biodistribution, and therapeutic efficacy have all been enhanced by developments in lipid chemistry, microfluidic manufacturing, surface engineering, and artificial intelligence-assisted formulation. However, obstacles to wider use still include low tissue specificity, ineffective endosomal escape, immunogenicity, production difficulties, and long-term safety. The evolution, composition, formulation, delivery methods, therapeutic uses, clinical translation, regulatory issues, and upcoming tactics like organ-selective targeting and CRISPR-Cas gene editing are all covered in this review.
No takes yet. Share an insight, caveat, or question.
Sable et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: